Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Response Predictors of S-1, Cisplatin, and Docetaxel Combination Chemotherapy for Metastatic Gastric Cancer: Microarray Analysis of Whole Human Genes.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: Karger Country of Publication: Switzerland NLM ID: 0135054 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1423-0232 (Electronic) Linking ISSN: 00302414 NLM ISO Abbreviation: Oncology Subsets: MEDLINE
- Publication Information:
Original Publication: Basel, New York, Karger.
- Subject Terms:
- Abstract:
Objectives: The aim of this study was to identify biomarkers for predicting the efficacy of docetaxel, cisplatin, and S-1 (DCS) therapy for advanced gastric cancer using microarrays of biopsy specimens before chemotherapy.
Methods: Nineteen samples were taken from 19 patients with unresectable metastatic gastric cancer who received DCS as a first-line therapy. Laser capture microdissection was performed, and total cellular RNA was extracted from each microdissected sample. Whole-gene expression was analyzed by microarray, and the difference in mRNA expression observed with the microarrays was confirmed by quantitative real-time PCR. Immunohistochemical staining was performed using clinical tissue sections obtained by endoscopic biopsy.
Results: Eleven patients were identified as early responders and 8 patients as nonresponders to DCS therapy. Twenty-nine genes showed significant differences in relative expression ratios between tumor and normal tissues. A classifier set of 29 genes had high accuracy (94.7%) for distinguishing gene expression between 11 early responders and 8 nonresponders. Decreasing the size of the classifier set to 4 genes (PDGFB, PCGF3, CISH, and ANXA5) increased the accuracy to 100%. Expression levels by real-time PCR for validation were well correlated with those 4 genes in microarrays.
Conclusion: The genes identified may serve as efficient biomarkers for personalized cancer-targeted therapy.
(© 2017 S. Karger AG, Basel.)
- Contributed Indexing:
Keywords: Chemotherapy; Gastric cancer; Microarray
- Accession Number:
0 (Antimetabolites, Antineoplastic)
0 (Drug Combinations)
0 (Taxoids)
150863-82-4 (S 1 (combination))
1548R74NSZ (Tegafur)
15H5577CQD (Docetaxel)
5VT6420TIG (Oxonic Acid)
Q20Q21Q62J (Cisplatin)
- Publication Date:
Date Created: 20170517 Date Completed: 20171023 Latest Revision: 20181202
- Publication Date:
20240829
- Accession Number:
10.1159/000464329
- Accession Number:
28511180
No Comments.